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Oncogenic transformation of mammary epithelial
cells by transforming growth factor beta
independent of mammary stem cell regulation
Karen A Dunphy1*, Jae-Hong Seo2, Daniel J Kim1, Amy L Roberts1, Luwei Tao1, James DiRenzo3,
Amanda L Balboni3, Giovanna M Crisi4, Mary J Hagen1, Thiruppavai Chandrasekaran1, Kelly J Gauger5,
Sallie Smith Schneider5 and D Joseph Jerry1,5*
Abstract
Background: Transforming growth factor beta (TGFβ) is transiently increased in the mammary gland during
involution and by radiation. While TGFβ normally has a tumour suppressor role, prolonged exposure to TGFβ can
induce an oncogenic epithelial to mesenchymal transition (EMT) program in permissive cells and initiate the
generation of cancer stem cells. Our objective is to mimic the transient exposure to TGFβ during involution to
determine the persistent effects on premalignant mammary epithelium.
Method: CDβGeo cells, a transplantable mouse mammary epithelial cell line, were treated in vitro for 14 days with
TGFβ (5 ng/ml). The cells were passaged for an additional 14 days in media without TGFβ and then assessed for
markers of EMT and transformation.
Results: The 14-day exposure to TGFβ induced EMT and transdifferentiation in vitro that persists after withdrawal of
TGFβ. TGFβ-treated cells are highly tumorigenic in vivo, producing invasive solid de-differentiated tumours (100%;
latency 6.7 weeks) compared to control (43%; latency 32.7 weeks). Although the TGFβ-treated cells have initiated a
persistent EMT program, the stem cell population was unchanged relative to the controls. The gene expression
profiles of TGFβ-treated cells demonstrate de-differentiation with decreases in the expression of genes that define
luminal, basal and stem cells. Additionally, the gene expression profiles demonstrate increases in markers of EMT,
growth factor signalling, TGFβ2 and changes in extra cellular matrix.
Conclusion: This model demonstrates full oncogenic EMT without an increase in stem cells, serving to separate
EMT markers from stem cell markers.
Keywords: Transforming growth factor beta, TGFβ, Epithelial to mesenchymal transition, EMT, Transdifferentiation
Background
Transforming growth factor beta (TGFβ) has paradoxical
roles in breast cancer acting as both a tumour suppressor
and tumour promoter [1-4]. In the normal mouse
mammary epithelium, tumour resistance is achieved
with TGFβ-mediated cell cycle arrest and apoptosis [5-7].
TGFβ also initiates epithelial-mesenchymal transition
(EMT) [2]; whereby epithelial cells lose cell adhesions and
polarity and assume a mesenchymal motile phenotype.
The EMT process is transient, and cells usually revert to
their former phenotype via mesenchymal-epithelial
transition (MET).
Transient non-oncogenic EMT is a normal cellular
program that initiates cell migration during embryogenesis
to direct organ development; and, in differentiated tissues,
directs wound healing, regeneration and remodelling [8].
TGFβ is normally expressed in the mammary gland and
contributes to spatial distribution of the epithelial tree
by regulating ductal elongation and branching [9,10].
Expression of TGFβ is increased during involution of the
mammary gland following pregnancy [11], and conse-
quently, TGFβ-mediated apoptosis and cell cycle arrest
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reduce epithelial content to proportions found in the
non-lactating gland [12,13]. Likewise, a natural transient
TGFβ-mediated EMT program is employed to remodel
the mammary ductal tree during the involution process.
However, elevated levels of TGFβ during pregnancy and
involution can initiate a persistent oncogenic EMT program
in premalignant epithelial cells leading to tumour initiation
and development of pregnancy associated breast cancer
(PABC) [14]. TGFβ is also activated by radiation therapy
[15,16], and may increase the metastatic behaviour of
an existing cancer by promoting EMT [17]. However,
TGFβ-mediated EMT is a rare event in vitro [18] and
experiments demonstrating TGFβ induction of persistent
oncogenic EMT are limited to mammary epithelial cells
that have already been transformed with activated Ras
oncogene [19-21] or cells that are persistently exposed
to TGFβ [22]. Normal mouse and human mammary
epithelial cells only undergo transient EMT in response to
TGFβ in vitro [23,24], but revert to an epithelial pheno-
type via MET after TGFβ withdrawal and remain non-
tumorigenic in vivo.
TGFβ-mediated EMT may also promote the generation
of cancer stem cells [20,25,26]. Induction of EMT and a
mesenchymal state increased the population of CD24Low
CD44High stem cells in mammary carcinoma cell lines
[27,28]. Because there is considerable overlap in gene
expression profiles linking cells undergoing EMT with
stem cells [29,30], including up-regulation of Snail, Zeb2
and down-regulation of Sfrp1 [31,32], signatures for EMT
and stem cells have been difficult to separate.
The CDβGeo mouse mammary epithelial cell line is a
heterogeneous population of K8+ luminal epithelial and
K5+ basal cells that are enriched for progenitors [33].
This cell line was derived from COMMA-D cells and,
although phenotypically heterogeneous, the cells are clonal
with respect for biallelic mutations in Trp53 [34].
These cells form epithelial ductal trees when transplanted
into cleared mouse mammary fat pads and are mildly
tumorigenic [35]. In our experiments using the CDβGeo
cell line, we have generated a model whereby this mouse
epithelial cell line is transformed by transient TGFβ-
treatment in vitro making it highly tumorigenic in vivo,
yet the increased tumorgenicity did not alter the stem
cell pool. The transient TGFβ-treatment stimulates an
autocrine TGFβ loop supporting persistent EMT with
sustained expression of Snail, but inhibition of TGFβRI
only imparts partial rescue.
Results
Transient TGFβ exposure causes persistent
transdifferentiation in CDβGeo cells
CDβGeo cells were passaged for 14 days in DMEM:F12
media with solvent control or 5 ng/ml TGFβ1 to mimic
mouse TGFβ exposures during involution (Figure 1A).
Morphological changes in the CDβGeo cells occurred
4–5 days after TGFβ exposure. In contrast to CDβGeo
cells maintained in control media which exhibit a cuboidal
epithelial phenotype and attained confluence several times
during the 14 day treatment period, TGFβ-treatment
reduced cell growth (Additional file 1: Figure S1A) and
cells exhibited a senescent phenotype (Figure 1B). After the
14 day treatment period, TGFβ was withdrawn and cells
recovered and grew to confluency. With the exception
of a few isolated epithelial-like patches, the TGFβ-treated
cells remained spindle-shaped and did not resume the
cuboidal epithelial phenotype (Figure 1B: compare day 28
and inset).
The TGFβ-treated CDβGeo cells have reduced expres-
sion of E-cadherin (p < 0.05) and significantly increased
expression of N-cadherin (p < 0.01) relative to CDβGeo
control cells after 14 days (Figure 1 C&D). The expression
of E-cadherin is further reduced in the ensuing 14 days
(day 28), even though TGFβ had been removed. Immuno-
fluorescence on day 28 demonstrates appropriate expression
of E-cadherin and actin at the cell borders of the epithelial
CDβGeo control cells (Figure 1E), while few TGFβ-treated
cells express any E-cadherin. In the TGFβ-treated cells,
the actin filaments are arranged in longitudinal lines of
stress, indicative of loss of epithelial phenotype and acqui-
sition of a mesenchymal phenotype. In cell culture, the
CDβGeo cells produce a heterogeneous cell population, in-
cluding cells that express the luminal epithelial cytokeratin
(K8) and a smaller percentage of cells that express the
basal cytokeratin (K5) (Figure 1F). Expression of K8 is
lost in the TGFβ-treated cells such that the K5 popula-
tion is increased (Additional file 1: Figure S1B). These
results support the conclusion that the CDβGeo cells
have undergone persistent transdifferentation. These
phenotypic changes were reversible after prolonged culture
(>10 passages) with E-cadherin levels being restored.
Henceforth the CDβGeo cells transiently treated with
TGFβ for 14 days that sustain EMT after withdrawal of
TGFβ will be referred to as persistently transdifferentiated
(pTD) cells.
The pTD cells have increased migration and
invasion capability
It is proposed that in cancer, EMT confers increased inva-
sive ability to cancer cells. Therefore, we compared the mi-
gration and invasion capability of the CDβGeo parental
cells and pTD cells. Scratch assays demonstrated that the
CDβGeo control cells retain cellular attachment and slowly
close the wound as an epithelial sheet (Figure 2A). In con-
trast, the pTD cells dissociate and migrate into the wound
individually, and consequently, fill the gap more quickly
and efficiently. Quantitative assessment of the migratory
capability though culture inserts toward a chemoattractant
(serum) shows that the pTD cells have enhanced migration
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capacity compared to CDβGeo control cells (p < 0.05;
Figure 2B) and a 3-fold greater invasive capability through
matrigel coated membranes (p < 0.01; Figure 2C).
The transplanted pTD cells are more tumorigenic in vivo
than parental CDβGeo cells
To compare their tumorgenicity, 50 000 CDβGeo paren-
tal cells and 50 000 pTD cells were transplanted into
contralateral cleared fat pads of thirteen 3-week old
BALB/c mice. Large tumours developed so rapidly from
the pTD transplants (100%; mean latency 6.7 weeks) that
the study had to be concluded by 13 weeks and did not
allow for adequate assessment of the CDβGeo parental
cells. Therefore, 50 000 CDβGeo cells were transplanted
into both cleared fat pads to allow assessment of
tumorgenicity of the parental cells (Figure 3A). CDβGeo
Figure 1 Transient TGFβ exposure causes persistent transdifferentiation in CDβGeo cells. (A) Description of experimental timeline – Cells
were cultured and passaged in control media for 28 days (CDβGeo control) or 5 ng/ml TGFβ for 14 days followed by passage in control media
for an additional 14 days. (B) The parental CDβGeo cells retain a cuboidal cobblestone morphology throughout the treatment period in the
control media, but during TGFβ-treatment cells become senescent, spindle-like and avoid adhesion. (C) Western blot analysis shows down-regulation
of E-cadherin and up-regulation of N-cadherin (D) Quantification of E-cadherin and N-cadherin protein expression, normalized to β-actin (* p < 0.05;
**p < 0.01). (E) Immunofluorescence for E-cadherin and Actin demonstrate appropriate expression in control cells. TGFβ-treated cells have reduced
E-cadherin expression and actin stress fibers. (F) K8 expression is reduced in TGFβ-treated cells.
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cells produce outgrowths with normal ducts as well as
alveolar hyperplasia. The outgrowths of CDβGeo cells
are pre-neoplastic, producing mammary tumours in
less than 43% of transplants with a longer mean latency
(32.7 weeks) compared to pTD cells (p < 0.001). These
results demonstrate that transient TGFβ-treatment
transforms mammary epithelial cells making them more
tumorigenic in vivo.
The characteristics of outgrowths and tumours from the
CDβGeo and pTD cells were determined using immuno-
histochemistry for estrogen receptor alpha (ERα) and K8
to define luminal cells and K5 to identify basal epithelia
(Figure 3B). CDβGeo outgrowths ranged from normal
glandular, ductal hyperplasia, ductal adenocarcinoma
with acinar morphology and, in some cases, solid de-
differentiated tumours. Most of the normal appearing
CDβGeo ductal outgrowths expressed ERα, K8 and K5
appropriately (Figure 3, left column). 56% of the CDβGeo
tumours examined were ERα positive, but there was no
correlation between the expression of ERα and tumour
development as some ductal structures were ERα negative
and some solid tumours were ERα positive. As outgrowths
progressed from normal-like, to ductal hyperplasia and
ductal adenocarcinoma, expression of both K8 and K5
were progressively lost. In contrast, the pTD outgrowths
did not have any normal ductal architecture. All the pTD
Figure 2 pTD cells have increased migration and invasion capability. (A) scratch assay demonstrates greater capability of pTD cells in
wound closure. (B) pTD cells have greater migration capacity (**p < 0.01) and (C) greater invasion capability (*p < 0.05).
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tumours were solid sheets of de-differentiated spindle like
cells (Figure 3B, right column). The pTD tumours were
locally invasive into muscle tissue and into the body cavity.
In the tumours that were positive for ERα (24%),
expression was weak. Likewise, expression of K8 and K5
were weak or absent. We conclude that transient in vitro
TGFβ-treatment advances the tumorgenicity of the cells
such that the pTD transplants produce more aggressive
solid de-differentiated tumours.
Characterization of gene expression changes in the
pTD cells
We also examined the transcriptional profiles of genes
differentially regulated relative to the CDβGeo parental
cells to further characterize the pTD cells. Analysis with
DAVID Bioinformatics Resources [36,37] using a subset
of 482 up-regulated and 563 down-regulated DAVID IDs
(>2-fold change; p < 0.05), identified significant increases
in ECM-receptor interactions and focal adhesion in the
pTD cells (Additional file 2: Table S1). The pTD cells also
demonstrated decreases in cell cycle, DNA replication,
p53 signalling and tight junction pathways. The normal
mammary duct is comprised of luminal epithelial cells,
basal cells and a small population of stem cells. Profiles
of genes defining luminal epithelial or basal cells are
decreased in the pTD cells relative to the CDβGeo cells
(Additional file 3: Figure S2A & B). Many luminal epi-
thelial junction proteins including the claudins, junction
plakoglobin (JUP), epithelial cell adhesion molecule
(EpCAM) and the epithelial keratins are down-regulated
in the pTD cells relative to the CDβGeo cells. Likewise,
basal keratins, smooth muscle actin and actin interacting
proteins are also down-regulated in the pTD cells. This
apparent de-differentiation of cultured cells by TGFβ-
treatment agrees with the loss of differentiation markers
in the pTD tumours. Genes in a profile that defines stem
cells are also down-regulated (Additional file 3: Figure S2C).
There are no increases in the surface markers used to sort
stem cells (CD44, CD49f, or CD29) and no increase in
stem cell associated transcription factors (Hey1, Nanog,
Pou5F1/Oct4 or Sox9). However, Snai2, up-regulated
during EMT and in stem cells, is increased in the pTD
cells (Additional file 3: Figure S2D). Profiles defining
genes regulated during EMT are persistently altered in the
pTD cells, including, 2-fold up-regulation of fibronectin,
N-cadherin, vimentin, Snai1, Twist, and many matrix
metalloproteinases (MMP), along with 2-fold down-
regulation of E-cadherin (Cdh1), bone morphogenic
proteins (BMPs), and secreted frizzled-related protein
(Sfrp1) (p < 0.05). There are also significant changes in
the expression of components of the ECM. The pTD
cells also have increased expression of growth factor
promotion genes including growth factors, cytokines
and growth factor receptors, while tumour suppressors
are down-regulated. We conclude that transient TGFβ-
treatment transforms CDβGeo cells such that they are de-
differentiated and persistently transdifferentiated with
increased expression of EMT markers, changes in
Figure 3 Transplanted pTD cells are more tumorigenic in vivo
than parental CDβGeo cells. (A) Survival curve for mammary tumour
incidence in weeks. pTD cell transplants are significantly more
tumorigenic than CDβGeo cells (p < 0.01). (B) Immunohistochemistry
for CDβGeo normal-like ductal outgrowth (first column), hyperplastic
outgrowth (second column), acinar adinocarcinoma (third column) and
pTD tumours (fourth column): hematoxylin and eosin stain (first row);
ERα expression (second row); immunofluorescence for K8 (third row); K5
(fourth row); Dapi (fifth row) and merge (sixth row). Scale bar = 20 μm.
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ECM components and increased sensitivity to tumour
promotion.
Persistently transdifferentiated pTD cells do not exhibit
an increase in the stem cell pool
Previous reports suggest that the population of stem cells
is increased during the implementation of a transient
EMT program [20,25,26]. Because stem cell profiles and
EMT profiles overlap, and because the pTD cells demon-
strate persistent EMT-mediated changes in gene expression
without increases in select stem cell genes, we compared
stem cell ratios relative to the CDβGeo parental cells using
three distinct assays. During the TGFβ exposure period,
the mammosphere forming capability is transiently in-
creased (Additional file 4: Figure S3), but although
EMT is persistent 14 days after withdrawal of TGFβ, on
day 28 there was no increase in primary or secondary
mammosphere formation (Figure 4A). FACs analysis also
shows no difference in aldefluor positive cells or changes
in the CD44High CD24Low population (Figure 4 B&C). The
let-7c sensor assay, which utilizes the fact that stem cells
express very low let7c microRNA [38], also demonstrates
no differences in the proportion of stem cells between the
CDβGeo and pTD cells (Figure 4D). A limiting dilution
series also shows that the CDβGeo cells and the pTD cells
have similar capacity to repopulate in the mammary gland
(Figure 4E). Specifically, partial growth (<50% of fat
pad filled) occurred equally between the two cell types
when 5000 (2/5) or 1000 (1/5) cells were transplanted.
Regardless of the number of cells transplanted, the success-
ful pTD outgrowths always produced solid tumours, even
when examined as early as three weeks after transplant-
ation. We find no evidence that there is an increase in the
stem cell population in the pTD cells.
Expression of snail, Zeb2 and Sfrp1 are altered in
transdifferentiated cells
Up-regulation of Snail and Zeb2, along with repressed
expression of Sfrp1, are features of EMT which contribute
to mammary tumours [31,39]. As expected, quantitative
RT-PCR demonstrates elevated expression of both Snail
and Zeb2 in the pTD cells (2-fold) and tumours (>4-fold)
Figure 4 Persistently transdifferentiated pTD cells do not have an increase in the stem cell pool. (A) Initiation of primary or secondary
mammospheres are not different between CDβGeo cells and pTD cells. (B) FACS for Aldefluor. (C) FACS for CD44 CD24. (D) FACS for Let7c
sensor. (E) Limiting dilution for CDβGeo and pTD cells.
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relative to the CDβGeo cells along with suppression of
Sfrp1 (Figure 5A). The expression changes in these three
genes serve as an indication of EMT.
Persistent EMT does not occur in mammary epithelial
cells unless they have already been transformed by an
oncogenic mutation; specifically activated Ras [21,25]. As
CDβGeo cells are p53-deficient [34] we tested the effect of
p53-deficiency in rendering cells permissive to EMT. The
TM40A mammary epithelial cell line is also derived from
BALB/c mice, but retains wildtype p53 and are non-
tumorigenic [38]. The TM40A cells do not undergo EMT
in response to TGFβ-treatment, and cells expressing
siRNA to knock down p53 (TM40A si-p53) also do not
undergo EMT in response to TGFβ. Likewise, there are
no differences in the expression of Snail, Zeb2 or Sfrp1
between TM40A control, TM40A TGFβ-treated, TM40A
p53 si-control or TM40A si-p53 following TGFβ treatment
(Figure 5B). We conclude that p53 deficiency does not
contribute to sustained EMT and transdifferentiation in
the CDβGeo cells by TGFβ.
In contrast to CDβGeo cells, basal levels of Snail and
Zeb2 are significantly lower (p < 0.01) in the TM40A cells
and were not altered by TGFβ. The TM40A cells are
responsive to TGFβ as determined by CAGA-luciferase
reporter assay (Additional file 5: Figure S4A). Likewise,
another mouse mammary cell line, NMuMG, also has
lower endogenous Snail expression relative to CDβGeo
cells (Additional file 5: Figure S4B), and this cell line has
been shown to be only capable of transient EMT in re-
sponse to TGFβ [23]. These results suggest that the elevated
endogenous levels of Snail and Zeb2 may render CDβGeo
cells sensitive to transdifferentiation by TGFβ.
Figure 5 Expression of Snail, Zeb2 and Sfrp1 are altered in transdifferentiated cells. (A) QPCR expression of Snail, Zeb2 and Sfrp1 in pTD
cells and tumours relative to CDβGeo. (B) QPCR expression of Snail, Zeb2 and Sfrp1 relative to CDβGeo cells in TM40A cells with wild type p53 or
p53 knock-down maintained in control media or TGFβ media. *p < 0.05; **p < 0.01. (C) Changes in expression of Snail, Zeb2 and Sfrp1 relative to
CDβGeo cells (*p < 0.05, **p < 0.01) and relative to pTD cells (#p < 0.05, ##p < 0.01) after 24 hour treatment with TGFβ inhibitor LY364947 and
48 hours after withdrawal of LY364947 demonstrate that autocrine production of TGFβ2 may support persistent EMT.
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Autocrine production of TGFβ2 contributes to
persistent EMT
The expression of ligands in the transforming growth fac-
tor beta superfamily identified persistent up-regulation of
TGFβ2 (p < 0.01) in pTD cells. Autocrine production
of TGFβ ligand can support EMT and tumorigenesis
[21,40,41]. To test if persistent EMT was maintained by
an autocrine TGFβ positive feedback loop, we examined
the expression of Snail, Zeb2 and Sfrp1 during and after
treatment with the TGFβRI inhibitor LY364957 (10 μM).
LY364957-treatment had no effect on the parental CDβGeo
cells, neither at 24 hours after treatment nor subsequent
to a 24 hour inhibitor treatment followed by a 48 hour
withdrawal of inhibitor (Figure 5C). However, there is
partial suppression of Snail expression in the pTD cells
relative to pTD control (p < 0.05) after treatment with the
inhibitor that is sustained after inhibitor withdrawal.
Sfrp1 expression is also restored after 24 hour LY364947-
treatment, but Sfrp1 rescue is not sustained after removal
of the inhibitor. Inhibition of autocrine TGFβ signalling
had no effect on Zeb2 expression in the pTD cells. These
results demonstrate that in persistently transdifferentiated
mouse mammary epithelial cells, a transient 24 hour block
of autocrine TGFβ signalling can initiate a partial rescue
of gene expression for Snail and Sfrp1, but not Zeb2.
Discussion
CDβGeo transplants are considered premalignant because
they form hyperplastic outgrowths, some of which pro-
gress to invasive tumours. Transient TGFβ-treatment of
CDβGeo cells in vitro promotes EMT that is sustained
after withdrawal (designated pTD cells) and transforms
these mammary epithelial cells such that they become
mesencymal-like and highly tumorigenic in vivo. The pTD
cells, and the tumours that develop from them, are
de-differentiated, having lost markers that define both
luminal epithelial and myoepithelial cells. Interestingly,
there is no comprehensive acquisition of stem cell markers,
but rather decreased expression of several key stem cell
markers including CD44, CD49f, CD29 and Sox9, with no
change in the expression of Nanog or Pou5f1 (Oct4). This
is consistent with Nguyen et al., who demonstrate that
induction of TGFβ only accelerates tumorigenesis, and
that radiation-induced notch signalling is required for
expansion of mammary stem cells [42]. Although EMT
has been reported to increase the population of cells
with stem-like characteristics [20,25,43], TGFβ-induced
persistent EMT in the CDβGeo cells was not accompanied
by increases in the stem cell pool. Although CDβGeo cells
clearly have mammary progenitors [33] the mammosphere
forming capacity and transplant capability is similar to
primary mouse mammary epithelial cells [44]. Similar
to other reports [45,46], these cells do show enrichment
of the stem cell pool during TGFβ-treatment in vitro
(Additional file 4: Figure S3), but enrichment is transient,
and the equilibrium in cell populations is restored
upon subsequent passages and may not be essential for
tumours.
The cancer stem cell theory proposes that only a small
subset of cells, the tumour initiating cells, can seed a new
tumour or a metastasis [47]. Therefore, there is great
interest in identifying cancer stem cells in order to identify
pathways and targets to reduce the metastatic potential
of cancer. However, the defining line between EMT,
mesenchymal cells, cancer stem cells and bulk tumour
cells is indistinct [48,49] with substantial overlap among
makers of EMT and profiles to define stem cells [29,30].
These signatures also align with human claudin-low and
metaplastic breast cancers [41], although clearly these are
not the only tumours with metastatic potential. The
CDβGeo model identifies changes in ECM, MMPs, and
transcription factors such as Snai1, Snai2, and Zeb2 as
indicative of EMT. Because our model represents EMT
without changes in the stem cell population, it suggests
that ITGA6, DUSP6, Sox9, and KLF4 are valid markers
for stem cells as suggested by Gupta et al. [45]. Because
pTD cells demonstrate persistent EMT without increases
in the stem cell pool, this model can be used to separate
markers for EMT and consequently refine signatures that
define tumour initiating cells.
Previous work has demonstrated that transdifferentiation
of mammary epithelium in response to TGFβ-treatment is
transient [19,24] and that sustained transdifferentiation
and tumorigenesis in vivo only occurs with sustained
TGFβ exposure or transformation with v-Ha-Ras oncogene
[19]. Deletion of p53 also promotes EMT by releasing the
repression of Zeb1, Zeb2 and BMI1 [50]. However, our
experiments with TM40A cells show that blocking p53
is not sufficient for TGFβ-mediated EMT. Additionally,
even though the CDβGeo cells are p53-deficient, cell
growth was repressed by TGFβ. This agrees with other
reports that TGFβ-mediated cell cycle arrest is p53-
independent [51] and that p63/p73 may compensate in
TGFβ-mediated pathways [52], including possibly those
that promote EMT.
Persistent EMT has also been shown to be dependent on
sustained TGFβ exposure through an autocrine positive
loop [21,32,40,53]. The pTD cells have elevated TGFβ2
and there is partial rescue, with decreased expression of
Snail and increased expression of Sfrp1, when the pTD
cells are treated with the TGFβRI inhibitor LY364947.
While higher doses of the TGFβRI inhibitor or a longer
course of treatment may achieve a more robust rescue, the
transcriptional profiles suggest that the transformed pTD
cells have undergone epigenetic modifications, affecting
multiple pathways, such that targeting TGFβ-pathways
alone will not be effective. With extended expansion
in culture (>5-10 additional passages), the pTD cells
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gradually regain a cobblestone epithelial morphology
in vitro. This partial MET in vitro may be due to the
dilution, during sequential passaging, of TGFβ2 and other
factors that support the mesenchymal phenotype. EMT
and acquisition of mesenchymal properties are necessary
for some metastatic processes including intravasation,
transport in circulation and extravasation. Dilution of
mesenchymal supporting factors during dissemination
may explain the paradox of why secondary tumours often
exhibit an epithelial phenotype rather than a mesenchymal
phenotype [54].
Conclusions
Characteristics defining EMT and cancer stem cells are
often synonymous. The CDβGeo model reveals that EMT
is a separable state from stem cells; facilitating distinction
to reveal targets important for the prevention and treat-
ment of breast cancer metastasis. While our model reveals
that the persistent EMT phenotype of the pTD cells are
maintained by autocrine production of TGFβ2, targeting
a single pathway (via TGFβ-inhibition) is not sufficient,
illustrating the necessity of therapeutics targeting multiple
pathways. Drugs targeting chromatin and epigenetic path-
ways offer a potentially valuable mechanism to silence
EMT regulated genes and reverse oncogenic EMT.
Methods
Mice
All animals were bred and maintained in accordance
with procedures approved by the Institutional Animal
Care and Use Committee. 4th inguinal mammary fat
pads were cleared as described [55] in female BALB/cMed
recipient mice. CDβGeo and pTD cells (50 000 cells/10 μl)
were injected with a Hamilton syringe and 30-guage
needle into contra-lateral glands of thirteen hosts for
tumour studies and were monitored for 13 weeks. Twelve
additional mice received CDβGeo cells only in both glands
and were monitored for 40 weeks. Cell and number of
recipients for the limiting dilution experiments are
described in Figure 4E. Glands for limiting dilution
were processed for whole mounts as described [56] at
5 weeks to ascertain outgrowth potential.
Cell culture and retroviral infection
CDβGeo cells were maintained in DMEM:F12 media
(Sigma) supplemented with 2% adult bovine serum (Gibco),
10 μg/ml insulin (Sigma), 5 ng/ml mouse Epidermal
Growth Factor (mEGF) and 100 U/ml Pen/Strep. pTD
cells were generated by treating CDβGeo cells with 5 ng/ml
TGFβ1 (R&D Systems Inc.) for 14 days during which
control and treated cells were passaged 5 times to a
similar density (1.2×106 cells/100 mm plate every 3 days).
Cell number and percent growth inhibition was determined
with Vi-Cell cell viability analyzer (Beckman Coulter).
Following the treatment period, the pTD and control
cells were passaged (5 times) in maintenance media for
an additional 14 days. (Figure 1A). TM40A-si-control and
TM40A-si-p53 cells were generated and maintained as
described previously [38] and treated with TGFβ or
control solvent as described above.
Flow cytometry
Fluorescence-Activated Cell Sorting (FACS) data were col-
lected using LSRII (Becton Dickinson). A total of 100 000
events were collected and analyzed using DB FACSDiva
software (Becton Dickinson).
Immunocytochemistry, immunofluroescence and
western blots
For cell culture, cells were grown to 100% confluency on
laminin coated (2 μg/cm2) Lab-TekII glass chamber
slides (154526, Nunc, Denmark). Cells were fixed with
2% paraformaldehyde, permeabilized with Karsenti’s
Buffer (80 mM PIPES, 5 mM EGTA, 1 MM MgSO4, 0.5%
Triton X-100), blocked in Protein Block (×0909; Dako)
20 minutes and incubated sequentially with primary
antibody for 1 hour followed by secondary antibody for
1 hour.
CDβGeo and pTD outgrowth sections were deparaffinized
and rehydrated prior to antigen retrieval in 10 mM citrate
buffer for 20 minutes at 100°C. Primary antibodies for K5,
K8 or ERα (MC-20) were used. Hematoxylin was used as
a counterstain for ERα, while DAPI was used for immuno-
fluorescence. All images were captured using a Nikon
Eclipse TE2000-U and Metaview™ software (Universal
Imaging Corporation). The Allred scoring system was
used to determine ERα expression.
Cells were lysed with RIPA buffer (50 mM Tris,
150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1%
NaDeoxycholate [pH 7.4] supplemented with protease
inhibitors (1 mM phenylmethylsulfonyl fluoride, 10 μg/ml
pepstatin A, 10 μg/ml aprotinin, and 5 μg/ml leupeptin).
Protein lysates were resolved by SDS-polyacrylamide gel
electrophoresis (PAGE) and transferred onto Polyvinylidene
Fluoride membrane (Millipore). Non-specific binding
was blocked with PBS containing 0.2% Tween 20 and
5% nonfat dry milk, and blots were incubated 1 hour
with primary antibody followed by incubation with
horseradish peroxidase-conjugated secondary antibody,
developed using enhanced chemiluminescence solution
and visualized in G-Box imaging system (Syngene).
Antibodies used are listed in Table 1.
Luciferase assay
CDβGeo, NMuMG and TM40A cells were transfected
with 4 μg CAGA-luciferase plasmid and 0.05 μg Renilla
(pRL-CMV) plasmid using Lipofectamine 2000 (Invitrogen).
Luciferase assay was performed using Dual Luciferase
Dunphy et al. Cancer Cell International 2013, 13:74 Page 9 of 12
http://www.cancerci.com/content/13/1/74
Reporter Assay (Promega) and a 20/20n Luminomer
(Turner Biosystems).
Mammosphere culture
CDβGeo cells and pTD cells were seeded at a density of
20 000 viable cells/ml in ultra low attachment dishes
(3473, Corning Life Sciences) as described [38]. After
collecting primary mammospheres with gentle centrifu-
gation at 800 rpm for 5 minutes, cells were dissociated
with 1 ml 0.05% trypsin-EDTA for 5–8 minutes and single
cells were obtained by filtering cell suspension through a
40 μm cell strainer. Cells for secondary mammospheres
were seeded at a density of 1000 viable cells/ml. Primary
and secondary mammospheres were quantified by counting
spheres >200 μm.
Migration and invasion assays
For the scratch assay, CDβGeo and pTD cells were grown
to 80% confluence. The wound was generated across the
plate with a pipette tip. Images were captured every
2 hours for 12 hours with a Nikon Eclipse TE2000-U and
Metaview™ software (Universal Imaging Corporation). For
chamber migration assays, CDβGeo and pTD cells were
seeded in serum free media into either BD BioCoat control
chambers (25 000 cells/ml) or Matrigel™ invasion chambers
(100 000 cells/ml) (BD Bio-sciences). Media containing
10% FBS was used as an attractant. After 22 hours incuba-
tion, cells were fixed for 10 minutes in 10% formalin,
stained with Crystal Violet and membranes were mounted
on microscope slides. Images were captured with an
Olympic BX41 light microscope using SPOTSOFTWARE
(Diagnostic Instruments, Inc.) and quantified using Image J.
RNA isolation for quantitative RT-PCR and microarray
Total RNA was extracted using Trizol reagent according
to manufacturer’s instructions (Invitrogen) and cleaned
up with Qiagen RNeasy (Qiagen). Relative levels of
mRNA were determined by quantitative real-time
PCR. The assays were performed using the 1-step Bril-
liant® SYBR® Green QRT-PCR Master Mix Kit
(Stratagene); primer sequences are listed in Table 2 and
described previously [31].
RNA samples (10 μg) were processed by the UCLA
Microarray Core Facility and hybridized to the Affymetrix
Mouse Genome 430 2.0 array (Affymetrix). The quality of
the RNA and labelled cRNA were determined using the
RNA 6000 Nano-LabChips (Agilent Technologies). Array
quality, background correction and data normalization of
gene expression data were computed directly from the
Affymetrix. CEL files using the Bioconductor packages for
R [57] implementation of affyPLM and Robust Multichip
Average [58-60]. Differential expression of genes was
determined using TM4 software [61]. Pair wise compar-
isons of each treatment relative to the vehicle-treated
group was used to identify statistically differentially
expressed probes (Welch’s t-test; P < 0.05 calculated from
1000 permutations of the expression data for each gene).
DAVID [36,37] was used to investigate differences in
signalling pathways. The genes for DAVID analysis were
selected for >2-fold differences relative to control. The
gene lists identifying Luminal, Basal, Stem Cells, EMT,
ECM and Growth Factor Signalling were selected from
those published previously [29,30,62-64].
Statistical analysis
The tumour-free survival was analyzed using survival
distribution with censoring in GraphPad Prism. The
differences in tumour incidences were determined by the
chi-square test and differences in expression in pTD cells
relative to CDβGeo control were determined using the
two-tailed Student’s t test. A p-value <0.05 was considered
statistically significant.
Table 1 Antibodies
Antigen Cat. # Source Dilution Application
E-cadherin 610181 BD Biosciences 1:2000 WB
1:50 IF
N-cadherin 610910 BD Biosciences 1:2000 WB
β-actin 4967 Cell Signaling 1:4000 WB
ZO-1 339100 Invitrogen 1:100 IF
K5 PRB-160 Covance 1:100 IF
K8 GP11 Progen Biotechnik 1:50 IF
ER (MC20) SC545 Santa Cruz 1:200 IHC
AlexaFluor 568 conjugated phalloidin A12380 Invitrogen 1:40 IF against actin
Table 2 Primer sequences
mRNA Forward Reverse
Snail gtctgcacgacctgtggaa caggagaatggcttctcacc
Zeb2 ccagaggaaacaaggatttca aggcctgacatgtagtcttgtg
Sfrp1 gctgctcaacaagaactgccacat acatttgagcatctcgggccagta
Pgk1 tgactttggacaagctggacgtga tgagttcagcagcaactggctcta
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Additional files
Additional file 1: Figure S1. (A) TGFβ-treatment restricts the growth of
CDβGeo cells (percent relative to mean control) and (B) Quantification of
immunofluorescence demonstrates TGFβ-treatment increases the K5
positive cell population (p < 0.05).
Additional file 2: Table S1. DAVID Bioinformatics Database
Annotation Summaries for pathways (KEGG_Pathway).
Additional file 3: Figure S2. Characterization of gene expression
changes in the pTD cells. Gene profiles in the pTD cells relative to the
CDβGeo parental cells that characterize specific mammary cell types
show decreased expression (green) for (A) luminal epithelium, (B) basal
epithelium, and (C) stem cells. (D) An EMT gene profile shows increased
expression (red) for genes up-regulated during EMT (CAV1 to ZEB2) and
decreased expression (green) for genes down-regulated during EMT
(BMP to WNT7B). (E) Expression changes in ECM genes. (F) Many growth
factors, cytokines and receptors are up-regulated (red) while tumour
suppressors are down-regulated (green). Log2 expression changes in
CDβGeo and pTD cells relative to mean CDβGeo are shown in A-C. Mean
log2 expression changes in the pTD cells relative to mean CDβGeo are
shown in E-G.
Additional file 4: Figure S3. Mammosphere forming capability is
increased by TGFβ during (day 12) TGFβ-treatment (p < 0.01).
Additional file 5: Figure S4. (A) Fold increase in TGFβ-induced
luciferase in mouse mammary cell lines. (B) Endogenous Snail expression
is lower in cell lines that fail to undergo persistent EMT in response to
TGFβ. (Also shown for comparison expression of Pgk1 normaliser with
normalized and non-normalized Snail expression; p < 0.01).
Abbreviations
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associated breast cancer; pTD: persistently transdifferentiated CDβGeo cells;
K8: Cytokeratin 8; K5: Cytokeratin 5; ERα: Estrogen receptor alpha;
MMP: Matrix metalloproteinase; BMP: Bone morphogenic protein.
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